Physician profile
Christopher B Rue
NPI 1689173296
$2,113.05
in general payments reported to CMS, 2019-2025
21 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.11 · 2022: $503 · 2023: $741 · 2024: $434 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $473.33 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $198.89 | 2022-2025 | |
| Dexcom, INC. | $172.93 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.69 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $133.59 | 2022-2023 | Farxiga |
| Axsome Therapeutics, INC. | $124.99 | 2024 | Auvelity |
| Bioxcel Therapeutics, INC. | $124.99 | 2023 | Igalmi |
| Merck Sharp & Dohme LLC | $122.30 | 2022-2023 | Verquvo |
| Janssen Biotech, INC. | $118.02 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.99 | 2024 | |
| Neurocrine Biosciences, INC. | $94.11 | 2021 | |
| Glaxosmithkline, LLC. | $51.89 | 2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $35.47 | 2022-2023 | Eliquis |
| Pfizer INC. | $34.53 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.31 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.29 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $32.16 | 2022 | |
| Astellas Pharma US INC | $20.74 | 2023 | Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $18.46 | 2024 | Rexulti |
| Novo Nordisk INC | $14.50 | 2022 | |
| Esperion Therapeutics, INC. | $13.87 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.